John Deakin-Bell

Stock Analyst at Citigroup

(0.37)
# 4,231
Out of 5,044 analysts
3
Total ratings
33.33%
Success rate
-11.89%
Average return
Main Sectors:

Stocks Rated by John Deakin-Bell

ResMed
Sep 8, 2022
Upgrades: Buy
Price Target: n/a
Current: $256.57
Upside: -